Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 1
Brief Summary: After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI). Subjects will then be randomized to receive any one of the 3 treatments (umeclidinium bromide \[UMEC\] \[62.5 mcg\] administered once daily via a DPI; OR UMEC \[125 mcg\] administered once daily via a DPI; OR matching placebo administered once daily via a DPI), while continuing treatment with open label FF/VI 100/25 mcg during a 12-week treatment period. There will be a total of eight scheduled clinic visits at Pre-Screening (Visit0), Screening (Visit 1), blinded treatment Day 1(Visit2), 2(Visit3), 28 (Visit4), 56 (Visit5), 84 (Visit6) and 85 (Visit7). A follow-up phone contact will be conducted approximately 7 days after the last clinic visit. The total duration of subject participation in the study from Screening to Follow-up will be approximately 17 weeks.


Options:
A: Arm Label: FF/VI 100/25 mcg + UMEC (62.5mcg); Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: UMEC | Arm Label: FF/VI 100/25 mcg + UMEC (125mcg); Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: UMEC | Arm Label: FF/VI 100/25 mcg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: Placebo | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo, FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: VI; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo, FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: UMEC; Assigned to Arm(s): FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo
B: Arm Label: Umeclidinium/vilanterol Arm; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/vilanterol, Drug: Placebo | Arm Label: Fluticasone propionate/salmeterol Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol, Drug: Placebo | Intervention Type: DRUG; Name: Umeclidinium/vilanterol; Assigned to Arm(s): Umeclidinium/vilanterol Arm | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm, Umeclidinium/vilanterol Arm
C: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 125mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo only | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: GSK573719 125mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GW642444 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo only; Assigned to Arm(s): Placebo

Answer: A